272 related articles for article (PubMed ID: 29991580)
21. Which is the better strategy in patients with cystic pancreas lesions?
Felderbauer P; Bulut K
Clin Gastroenterol Hepatol; 2007 Apr; 5(4):522; author reply 522. PubMed ID: 17445757
[No Abstract] [Full Text] [Related]
22. Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.
Christodoulou E; Visser M; Potjer TP; van der Stoep N; Rodríguez-Girondo M; van Doorn R; Gruis N
Fam Cancer; 2019 Oct; 18(4):439-444. PubMed ID: 31203567
[TBL] [Abstract][Full Text] [Related]
23. Can we predict the progression of premalignant pancreatic cystic tumors to ductal adenocarcinoma?
Chidambaram S; Kawka M; Gall TM; Cunningham D; Jiao LR
Future Oncol; 2022 Jul; 18(23):2605-2612. PubMed ID: 35730473
[TBL] [Abstract][Full Text] [Related]
24. TSPO-targeted PET and Optical Probes for the Detection and Localization of Premalignant and Malignant Pancreatic Lesions.
Cohen AS; Li J; Hight MR; McKinley E; Fu A; Payne A; Liu Y; Zhang D; Xie Q; Bai M; Ayers GD; Tantawy MN; Smith JA; Revetta F; Washington MK; Shi C; Merchant N; Manning HC
Clin Cancer Res; 2020 Nov; 26(22):5914-5925. PubMed ID: 32933996
[TBL] [Abstract][Full Text] [Related]
25. EUS-based Pancreatic Cancer Surveillance in
Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
[TBL] [Abstract][Full Text] [Related]
26. Risk Factors for Pancreatic Cancer and the Necessity of Long-Term Surveillance in Patients With Pancreatic Cystic Lesions.
Yoshioka T; Shigekawa M; Ikezawa K; Tamura T; Sato K; Urabe M; Sueyoshi H; Yamai T; Suda T; Sakamori R; Tatsumi T; Takehara T
Pancreas; 2020 Apr; 49(4):552-560. PubMed ID: 32282769
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
28. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals.
Overbeek KA; Goggins MG; Dbouk M; Levink IJM; Koopmann BDM; Chuidian M; Konings ICAW; Paiella S; Earl J; Fockens P; Gress TM; Ausems MGEM; Poley JW; Thosani NC; Half E; Lachter J; Stoffel EM; Kwon RS; Stoita A; Kastrinos F; Lucas AL; Syngal S; Brand RE; Chak A; Carrato A; Vleggaar FP; Bartsch DK; van Hooft JE; Cahen DL; Canto MI; Bruno MJ;
Gastroenterology; 2022 Mar; 162(3):772-785.e4. PubMed ID: 34678218
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).
de vos tot Nederveen Cappel WH; Offerhaus GJ; van Puijenbroek M; Caspers E; Gruis NA; De Snoo FA; Lamers CB; Griffioen G; Bergman W; Vasen HF; Morreau H
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3598-605. PubMed ID: 14506146
[TBL] [Abstract][Full Text] [Related]
30. Long-term yield of pancreatic cancer surveillance in high-risk individuals.
Overbeek KA; Levink IJM; Koopmann BDM; Harinck F; Konings ICAW; Ausems MGEM; Wagner A; Fockens P; van Eijck CH; Groot Koerkamp B; Busch ORC; Besselink MG; Bastiaansen BAJ; van Driel LMJW; Erler NS; Vleggaar FP; Poley JW; Cahen DL; van Hooft JE; Bruno MJ;
Gut; 2022 Jun; 71(6):1152-1160. PubMed ID: 33820756
[TBL] [Abstract][Full Text] [Related]
31. Refinement of screening for familial pancreatic cancer.
Bartsch DK; Slater EP; Carrato A; Ibrahim IS; Guillen-Ponce C; Vasen HF; Matthäi E; Earl J; Jendryschek FS; Figiel J; Steinkamp M; Ramaswamy A; Vázquez-Sequeiros E; Muñoz-Beltran M; Montans J; Mocci E; Bonsing BA; Wasser M; Klöppel G; Langer P; Fendrich V; Gress TM
Gut; 2016 Aug; 65(8):1314-21. PubMed ID: 27222532
[TBL] [Abstract][Full Text] [Related]
32. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
[TBL] [Abstract][Full Text] [Related]
33. PanGen-Fam: Spanish registry of hereditary pancreatic cancer.
Mocci E; Guillen-Ponce C; Earl J; Marquez M; Solera J; Salazar-López MT; Calcedo-Arnáiz C; Vázquez-Sequeiros E; Montans J; Muñoz-Beltrán M; Vicente-Bártulos A; González-Gordaliza C; Sanjuanbenito A; Guerrero C; Mendía E; Lisa E; Lobo E; Martínez JC; Real FX; Malats N; Carrato A
Eur J Cancer; 2015 Sep; 51(14):1911-7. PubMed ID: 26212471
[TBL] [Abstract][Full Text] [Related]
34. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center.
Pergolini I; Sahora K; Ferrone CR; Morales-Oyarvide V; Wolpin BM; Mucci LA; Brugge WR; Mino-Kenudson M; Patino M; Sahani DV; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
Gastroenterology; 2017 Nov; 153(5):1284-1294.e1. PubMed ID: 28739282
[TBL] [Abstract][Full Text] [Related]
35. Value of additional endoscopic ultrasonography for surveillance after surgical removal of intraductal papillary mucinous neoplasms.
Kamata K; Takenaka M; Minaga K; Omoto S; Miyata T; Yamao K; Imai H; Nakai A; Tanaka H; Chiba Y; Watanabe T; Sakurai T; Nishida N; Chikugo T; Matsumoto I; Takeyama Y; Kitano M; Kudo M
Dig Endosc; 2018 Sep; 30(5):659-666. PubMed ID: 29675938
[TBL] [Abstract][Full Text] [Related]
36. Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues.
Aichler M; Seiler C; Tost M; Siveke J; Mazur PK; Da Silva-Buttkus P; Bartsch DK; Langer P; Chiblak S; Dürr A; Höfler H; Klöppel G; Müller-Decker K; Brielmeier M; Esposito I
J Pathol; 2012 Apr; 226(5):723-34. PubMed ID: 21984419
[TBL] [Abstract][Full Text] [Related]
37. Does a family history of pancreatic ductal adenocarcinoma and cyst size influence the follow-up strategy for intraductal papillary mucinous neoplasms of the pancreas?
Mandai K; Uno K; Yasuda K
Pancreas; 2014 Aug; 43(6):917-21. PubMed ID: 24743378
[TBL] [Abstract][Full Text] [Related]
38. Prevalence and outcomes of pancreatic cystic neoplasms in liver transplant recipients.
Liu K; Joshi V; van Camp L; Yang QW; Baars JE; Strasser SI; McCaughan GW; Majumdar A; Saxena P; Kaffes AJ
World J Gastroenterol; 2017 Dec; 23(48):8526-8532. PubMed ID: 29358860
[TBL] [Abstract][Full Text] [Related]
39. Epithelial Nr5a2 heterozygosity cooperates with mutant Kras in the development of pancreatic cystic lesions.
Cobo I; Iglesias M; Flández M; Verbeke C; Del Pozo N; Llorente M; Lawlor R; Luchini C; Rusev B; Scarpa A; Real FX
J Pathol; 2021 Feb; 253(2):174-185. PubMed ID: 33079429
[TBL] [Abstract][Full Text] [Related]
40. Long-Term Surveillance and Timeline of Progression of Presumed Low-Risk Intraductal Papillary Mucinous Neoplasms.
Kayal M; Luk L; Hecht EM; Do C; Schrope BA; Chabot JA; Gonda TA
AJR Am J Roentgenol; 2017 Aug; 209(2):320-326. PubMed ID: 28590817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
